Toward a Revised Definition of Thrombotic Microangiopathy

Thrombotic microangiopathies (TMAs) have traditionally been diagnosed based on the classical triad of consumptive thrombocytopenia, microangiopathic hemolytic anemia, and microvascular thrombosis, often affecting the kidneys, as originally been described by Moschcowitz in the 1920s.1 Since then, TMAs have been recognized as arising from a spectrum of potentially life-threatening syndromes with shared morphologic features, representing a common endpoint of severe microvascular injury and thrombosis.